T
CUE icon

Tidemark’s Cue Biopharma CUE Stock Holding History

Tidemark’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$345 Hold
50
– – ﹤0.01% 810
2025
Q4 		$458 Hold
50
– – ﹤0.01% 627
2025
Q3 		$1.08K Hold
50
– – ﹤0.01% 632
2025
Q2 		$1.02K Hold
50
– – ﹤0.01% 643
2025
Q1 		$1.37K Buy
+50
New +$1.86K ﹤0.01% 640

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

Tidemark's CUE Position: Q1 2026 in Review

Tidemark held its Cue Biopharma (CUE) position steady in Q1 2026 at 50 shares worth $345. The position accounts for ﹤0.01% of the portfolio, ranked #810.

Tidemark first reported a position in CUE in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.37K in Q1 2025. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Tidemark held 50 shares of Cue Biopharma worth $345 as of Q1 2026.
  • Tidemark left its Cue Biopharma share count unchanged in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of Tidemark's portfolio in Q1 2026, its #810 holding.
  • Tidemark first reported a position in Cue Biopharma in Q1 2025 and has held it in 5 quarters since.
  • Tidemark's Cue Biopharma position peaked at $1.37K in Q1 2025.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Tidemark's 13F filing for Q1 2026, filed 7 May 2026.